Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease (RAISE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03997760
Recruitment Status : Recruiting
First Posted : June 25, 2019
Last Update Posted : August 23, 2021
Sponsor:
Collaborator:
Takeda Development Center Americas, Inc.
Information provided by (Responsible Party):
Takeda ( Shire )

Brief Summary:

SHP655 is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of SHP655 in SCD participants.

Study participants will receive SHP655 or placebo on Day 1. Their SCD will be treated by their doctor according to their doctor's usual clinical practice.

During the study, participants will be asked to follow-up on 13 days following SHP655 or placebo administration for safety assessment. Maximum duration of participation is expected to be about 2 months


Condition or disease Intervention/treatment Phase
Sickle Cell Disease Drug: SHP655 Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health
Actual Study Start Date : October 21, 2019
Estimated Primary Completion Date : November 2, 2022
Estimated Study Completion Date : November 2, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: SHP655
Participants with baseline SCD will receive a single intravenous (IV) infusion at one of the 3 dose levels of 40, 80 and 160 International units per kilogram (IU/kg) in a dose escalation manner for 14 days.
Drug: SHP655
Participants will receive SHP655 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
Other Name: recombinant ADAMTS13

Placebo Comparator: Placebo
Participants will receive placebo matched to SHP655 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion for 14 days.
Other: Placebo
Participants will receive placebo matched to SHP655 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.




Primary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: From date of signing informed consent up to study completion (up to Day 31) ]
    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product or medicinal product. An AE can therefore be any unfavorable and unintended sign (including a clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not causality is suspected (ICH Guidance E2A 1995). A serious adverse event (SAE) is any untoward clinical manifestation of signs, symptoms or outcomes (whether considered related to investigational product or not and at any dose) which results in death, is life-threatening, requires inpatient hospitalization, prolongation of hospitalization, is an important medical event. Number of participants with AEs and SAEs will be assessed.

  2. Number of Participants With Binding and Inhibitory Antibodies to SHP655 [ Time Frame: From start of study treatment up to study completion (up to Day 31) ]
    The number of participants will be summarized by dose for binding and inhibitory antibodies to SHP655 and will be reported as AEs. The study completion date is defined as the date on which the last participant in the study completes the final assessments.


Secondary Outcome Measures :
  1. Incremental Recovery (IR) of ADAMTS13 Activity and ADAMTS13 Antigen [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    IR will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  2. Observed Maximum Concentration (Cmax) of ADAMTS13 Activity and ADAMTS13 Antigen [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    Cmax will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  3. Time to Reach Cmax (tmax) of ADAMTS13 Activity and ADAMTS13 Antigen [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    Tmax will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  4. Terminal Half-Life (t1/2) of ADAMTS13 Activity and ADAMTS13 Antigen [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    Terminal half-life (t1/2) will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  5. Mean Residence Time From Zero to Infinite (MRT0-Inf) of ADAMTS13 Activity and ADAMTS13 Antigen [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    MRT0-inf will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  6. Mean Residence Time From Zero to 72 hours Post-dose (MRT0-72) of ADAMTS13 Activity and ADAMTS13 Antigen [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, and 72 hours post-dose ]
    MRT0-72 will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  7. Area Under the Curve (AUC) From Zero to Time of Last Quantifiable Concentration (AUC0-Last) of ADAMTS13 Activity and ADAMTS13 Antigen [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    AUC0-last will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  8. Area Under the Curve Time Curve (AUC) From Zero to 72 hours Post-dose (AUC0-72) of ADAMTS13 Activity and ADAMTS13 Antigen [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, and 72 hours post-dose ]
    AUC0-72 will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  9. Area Under the Curve (AUC) From Zero to Infinite Time (AUC0-Inf) of ADAMTS13 Activity and ADAMTS13 Antigen [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    AUC0-inf will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  10. Systemic Clearance (CL) of ADAMTS13 Activity and ADAMTS13 Antigen [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    Systemic clearance (CL) will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  11. Volume of Distribution at Steady State (Vss) of ADAMTS13 Activity and ADAMTS13 Antigen. [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    Vss will be estimated for ADAMTS13 activity and ADAMTS13 antigen (ADAMTS13Ag) following SHP655 infusion.

  12. Von Willebrand Factor:antigen (VWF:Ag) [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    Plasma VWF:Ag a PD variable will be observed to evaluate the effect of SHP655 on VWF.

  13. Von Willebrand Factor:Ristocetin cofactor activity (VWF:RCo) [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    Plasma VWF:RCo a PD variable will be observed to evaluate the effect of SHP655 on VWF.

  14. Change From Baseline in Platelet Count up to Day 31 [ Time Frame: Baseline up to Day 31 ]
    Change from baseline in platelet count up to Day 31 will be assessed.

  15. Plasma Free Hemoglobin [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    The correlation of plasma free hemoglobin on SHP655 activity and VWF will be assessed.

  16. Plasma Thrombospondin Levels [ Time Frame: Pre-dose, 15 minutes, 1, 3, 8, 24, 72, 120, 168, 216, 288, and 744 hours post-dose ]
    The correlation of plasma free thrombospondin levels on SHP655 activity and VWF will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 to 65 years at the time of signing the informed consent.
  • An understanding, ability, and willingness to fully comply with study procedures and requirements.
  • Ability to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent to participate in the study.
  • Male or female with a documented history of HbSS or HbSβo thalassemia (based on clinical record of genetic, electrophoresis, or high-performance liquid chromatography testing).
  • Participant currently taking hydroxyurea must be on a stable dosing for 3 months at screening.

Exclusion Criteria:

  • The participant was diagnosed with acute VOC in the 21 days before dosing on Day 1.
  • The participant has undergone blood transfusion within the last 30 days or blood transfusion on greater than or equal to (>=) 2 occasions in the last 90 days, at Screening Visit.
  • The participant has a history of acquired or congenital thrombotic thrombocytopenic purpura.
  • The participant has serum creatinine level greater than (>) 1.2 milligrams per deciliter (mg/dL).
  • The participant has alanine transaminase >3* upper limit of normal (based on clinical laboratory normal range), direct bilirubin level >2 mg/dL, or indirect bilirubin level >5 mg/dL at the Screening Visit.
  • The participant has a hemoglobin level <5 grams per deciliter (g/dL) at the Screening Visit.
  • The participant has a platelet count of <100 000/cubic millimeter (mm^3) at the Screening Visit.
  • Signs or symptoms of infection requiring treatment with IV antibiotics during the Screening Period.
  • The participant has fever with body temperature of >=38.5 degree Celsius (ºC) (101.3 degree Fahrenheit [ºF]) at the Screening Visit or before dosing on Day 1.
  • The participant has Acute Chest Syndrome (ACS), diagnosed or strongly suspected, as evidenced by a new infiltrate on chest radiograph, and one or more of the following criteria:

    1. Fever with body temperature >39°C (102.2°F)
    2. Hypoxia (confirmed by arterial blood gases with partial pressure of arterial oxygen (PaO2) <70 millimeter of mercury [mmHg])
    3. Chest pain
    4. Suspicious findings on physical examination (tachypnea, intercostal retraction, wheezing, and/or rales)
  • The participant has recently (within the past 28 days, from Screening Visit) undergone major surgery, requires hospitalization, documented serious bacterial infection requiring antibiotic treatment, or significant bleeding.
  • The participant has had a recent (within the past 90 days, from Screening Visit) episode of stroke, transient ischemic attack, symptomatic pulmonary hypertension, or seizure.
  • Any history of hemorrhagic stroke or bleeding diathesis.
  • The participant has received any of the following protocol-restricted medicines: a) systemic steroid therapy within 48 hours before dosing, or there is the expectation that such therapy may be given during the study (inhaled or topical steroids are allowed); b) Anticoagulant or antiplatelet therapy within the past 3 weeks before dosing; c) crizanlizumab within the past 30 days before dosing; d) voxelotor within the past 14 days before dosing.
  • For participants receiving chronic or long-acting opioids, a change in dose or pain requiring medical attention in the past 14 days before dosing.
  • The participant has a medical or psychiatric condition that, in the opinion of the investigator, may pose a risk to the participant for participation or interfere with the conduct or results of the study.
  • The participant has received or plans to receive any other investigational agent within the 4 weeks prior to the study screening visit or during the course of the study.
  • There is the expectation that the participant will not be able to be followed for the duration of the study.
  • The participant is pregnant or lactating or a female of childbearing potential or male unable or unwilling to comply with birth control methods or abstinence until the end of study visit.
  • The participant with active use of illicit drugs (excluding marijuana) and/or alcohol dependence, as determined by the investigator.
  • The participant has been administered SHP655 previously.
  • Known life-threatening hypersensitivity reaction, including anaphylaxis, to the parent molecule ADAMTS-13, hamster protein, or other constituents of SHP655.
  • The participant has a positive test result for hepatitis B surface antigen, or hepatitis C antibody, or human immunodeficiency virus (HIV) antigen/antibody, at the Screening Visit. However, a subject with a hepatitis C antibody and a negative hepatitis C virus ribonucleic acid (RNA) polymerase chain reaction test is not excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03997760


Contacts
Layout table for location contacts
Contact: Takeda Contact +1 866 842 5335 ClinicalTransparency@takeda.com

Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35233
Contact: Site Contact    205-996-8765    jkanter@uabmc.edu   
Principal Investigator: Julie Kanter Washko, MD         
United States, Arkansas
Arkansas Children's Hospital Recruiting
Little Rock, Arkansas, United States, 77202
Contact: Site Contact    501-364-1100    secrary@uams.edu   
Principal Investigator: Shelley Crary, MD/MSCS         
United States, Colorado
University of Colorado Sickle Cell Treatment and Research Center Recruiting
Aurora, Colorado, United States, 80045
Contact: Site Contact    303-724-9070      
Principal Investigator: Kathryn Hassell, MD         
Sickle Cell Center Recruiting
Denver, Colorado, United States, 80262
Contact: Site Contact    303-724-9071    kathryn.hassell@cuanschutz.edu   
Principal Investigator: Kathryn Hassell         
United States, Illinois
University of Illinois Recruiting
Chicago, Illinois, United States, 60612-4325
Contact: Site Contact    312-996-5984    vgordeuk@uic.edu   
Principal Investigator: Victor Gordeuk         
United States, Louisiana
University Medical Center New Orleans Recruiting
New Orleans, Louisiana, United States, 70112
Contact: Site Contact    504-702-4410      
Principal Investigator: Jyotsna Fuloria, MD         
Ochsner Health System Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Site Contact    504-702-4410    jyotsna.fuloria@lcmchealth.org   
Principal Investigator: Jyotsna Fuloria         
United States, Maryland
Johns Hopkins University School Of Medicine Recruiting
Baltimore, Maryland, United States, 21218
Contact: Site Contact    410-502-7770    slanzkr@jhmi.edu   
Principal Investigator: Sophie Lanzkron         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27705
Contact: Site Contact    919-684-2985    john.strouse@duke.edu   
Principal Investigator: John Strouse         
East Carolina University Recruiting
Greenville, North Carolina, United States, 27858
Contact: Site Contact    252-744-3556    lilesd@ecu.edu   
Principal Investigator: Darla Liles         
United States, Ohio
Ohio State University Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Site Contact    614-293-2887    payal.desai@osumc.edu   
Principal Investigator: Payal Desai, MD         
United States, South Carolina
Medical University of South Carolina (MUSC) Recruiting
Charleston, South Carolina, United States, 29425
Contact: Site contact    843-876-0444    bergmans@musc.edu   
Principal Investigator: Shayla Bergmann         
United States, Tennessee
University of Tennessee -- Memphis Recruiting
Memphis, Tennessee, United States, 38163-2116
Contact: Site Contact    901-448-2813    kataga@uthsc.edu   
Principal Investigator: Kenneth Ataga, MD         
United States, Virginia
VCU Health - Research Parent Recruiting
Richmond, Virginia, United States, 23298
Contact: Site Contact    804-828-2161    wally.smith@vcuhealth.org   
Principal Investigator: Wally Smith, MD         
Sponsors and Collaborators
Shire
Takeda Development Center Americas, Inc.
Investigators
Layout table for investigator information
Study Director: Study Director Takeda
Additional Information:
Layout table for additonal information
Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT03997760    
Other Study ID Numbers: SHP655-101
First Posted: June 25, 2019    Key Record Dates
Last Update Posted: August 23, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
URL: https://vivli.org/ourmember/takeda/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn